These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15314708)

  • 1. [Platelet Adhesion Assay (PADA), a new quantitative test for assessment of platelet function and therapeutic drug monitoring of GPIIb/IIIa and ADP receptor antagonists].
    Schumann A; Wiesenburg A; Bucha E; Nowak G
    Hamostaseologie; 2004 Aug; 24(3):211-6. PubMed ID: 15314708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?
    Schumann A; Bucha E; Nowak G
    Semin Thromb Hemost; 2005; 31(4):476-81. PubMed ID: 16149027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
    Graff J; Harder S
    Semin Thromb Hemost; 2005; 31(4):482-5. PubMed ID: 16149028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
    Khaspekova SG; Ziuriaev IT; Iakushkin VV; Golubeva NV; Ruda MIa; Mazurov AV
    Kardiologiia; 2011; 51(7):4-7. PubMed ID: 21878077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW; Steinhubl SR; Lincoff AM; Coleman JC; Lee TT; Hillman RS; Coller BS
    Circulation; 1999 Feb; 99(5):620-5. PubMed ID: 9950658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
    Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
    J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quick simple method of determining platelet aggregability following glycoprotein IIb/IIIa receptor inhibitor administration.
    Poullis M
    Cardiology; 1999; 91(3):156-60. PubMed ID: 10516408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
    Saraf S; Wellsted D; Sharma S; Gorog DA
    Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
    Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.
    Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M
    Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.